Key result
Encorafenib plus binimetinib completely resolves right atrial metastasis in melanoma case.
Case Report (n=1)
No
This case highlights the potential for rapid regression of suspected cardiac melanoma metastases using targeted BRAF/MEK inhibition and underscores the importance of early echocardiographic screening in cardio-oncology.
A 38-year-old otherwise healthy man was referred to the Greater Poland Cancer Center with 3 palpable tumors.Two years earlier, he had undergone excision of a skin tumor but had missed the histopathological result (nodular melanoma, pT4b).Ultrasonography demonstrated multiple tumoral lesions in the left temporal, neck, and axillary regions, and the left pectoralis minor muscle.Biopsies and positron emission tomography were performed, confirming melanoma with metastases (Figure 1A).The patient was deemed eligible for systemic therapy with combined immune checkpoint inhibition (ICI) (nivolumab plus ipilimumab).Owing to the urgency of initiating treatment and the absence of a cardiac history, no baseline cardiac assessment was performed to avoid delaying therapy.After the first ICI cycle, the patient presented to his general practitioner with tachycardia and a dry cough.Interstitial pneumonia was suspected, and azithromycin was prescribed.Oncological follow-up revealed no major abnormalities apart from laboratory evidence of hyperthyroidism; How to cite: Jachimowska J, Synowiec Z, Katarzyński S, Olasińska-Wiśniewska A. Right atrial mass in metastatic melanoma: a cardio-oncology challenge.
No takes yet. Share an insight, caveat, or question.
Jachimowska et al. (2026) conducted a case report in Metastatic melanoma (n=1). Encorafenib and binimetinib was evaluated. Targeted BRAF/MEK inhibition with encorafenib and binimetinib led to complete resolution of a suspected right atrial metastasis in a 38-year-old man with metastatic melanoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: